Newsroom | 1672 results

TALLAHASSEE, Fla.--(BUSINESS WIRE)--Healthcare advocates from across Florida will emerge on the state capitol to speak out against drastic cuts to Florida’s AIDS Drug Assistance Program (ADAP), recently announced by the Florida Department of Health (FDOH), that will eliminate access to life-saving medication and healthcare needed by thousands living with HIV/AIDS. Beginning March 1, 2026, Florida ADAP will reduce the Federal Poverty Level (FPL) income eligibility threshold for uninsured clients...

LOS ANGELES--(BUSINESS WIRE)--Bloom: Celebrating AHF’s Activism Through Augmented Reality and Art--2 Night Only Art Exhibition in Hollywood, January 20 and 21...

LOS ANGELES--(BUSINESS WIRE)--Bloom: Celebrating AHF’s Activism Through Augmented Reality and Art--2 Night Only Art Exhibition in Hollywood, January 20 and 21...

LOS ANGELES--(BUSINESS WIRE)--AHF to ‘Stand Against Hate’ at Martin Luther King, Jr. Day Events Nationwide...

PORTO, Portugal--(BUSINESS WIRE)--FairJourney Bio (FJBio), a global leader in antibody discovery and development, announced today that its Chief Executive Officer, Dr. Werner Lanthaler, will present at the J.P. Morgan 2026 Healthcare Conference, taking place from January 12 – 15, 2026 in San Francisco, CA. With more than a decade of expertise, FJBio has supported over 250 clients across Pharma, Biotech and Academia and contributed to more than 19 antibodies advancing to clinical stage developme...

LOS ANGELES--(BUSINESS WIRE)--AHF Rose Parade® Float Honors ‘Food for Health’ Wildfire and Hunger Relief Efforts...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with the U.S. government designed to reduce drug costs for Americans, reinforcing the company’s long-standing commitment to U.S.-based innovation, affordability, and global health leadership. “This agreement reflects a foundational commitment to both affordability and future innovation, a commitment that we have long seen as essential to shaping the future of healthcare,” said Daniel O’Day, C...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Keeley Wettan will be appointed Executive Vice President, General Counsel, Legal & Compliance effective immediately. She will join the company’s senior leadership team and report to Chairman and Chief Executive Officer Daniel O’Day. Ms. Wettan has held increasingly senior legal leadership roles within Gilead during her 14-year tenure, most recently as Senior Vice President leading the Global Lega...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment responses of adults with HIV who are virologically suppressed switching from BIKTARVY® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to a fixed-dose combination of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN). BIC/LEN efficacy was found to be statistically non...

LOS ANGELES--(BUSINESS WIRE)--New Billboards Mark AHF’s 50 Country Milestone, Promote Ease of Testing...